Physician profile
James Rabalais
NPI 1740691831
$10,019.09
in general payments reported to CMS, 2019-2025
21 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 85% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,992 · 2020: $887 · 2021: $844 · 2022: $1,771 · 2023: $871 · 2024: $1,315 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557 · Travel and Lodging: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.55 |
| Travel and Lodging | $968.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,164.71 | 2019-2024 | Senza, Vyrsa V1 |
| Boston Scientific Corporation | $1,453.45 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Saluda Medical Americas, INC. | $1,337.39 | 2023-2025 | Evoke, Evoke Scs |
| Stryker Corporation | $1,235.65 | 2020-2025 | Augment Injectable, Spinejack, Multigen 2 |
| Medtronic USA, INC. | $1,078.50 | 2019-2020 | |
| Abbott Laboratories | $796.42 | 2019-2025 | Eterna, Swift-Lock, Eon C |
| Globus Medical, INC. | $200.62 | 2025 | Vyrsa V1, Senza |
| Avanos Medical | $192.14 | 2019 | |
| Biotronik Nro, INC. | $121.82 | 2025 | Prospera |
| Medtronic, INC. | $79.25 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.79 | 2020-2025 | Relistor |
| Valinor Pharma, LLC | $62.90 | 2023-2024 | Movantik |
| Spr Therapeutics, INC | $49.04 | 2025 | Sprint Pns System |
| Arbor Pharmaceuticals, INC. | $36.71 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $32.68 | 2023-2024 | Horizant, Horizant |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $21.97 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.85 | 2025 | Iovera, Zilretta, Exparel |
| Spinal Simplicity, LLC | $18.01 | 2024 | Ha Minuteman G3-R |
| Relievant Medsystems, INC. | $13.93 | 2023 | Intracept |
| Assertio Therapeutics, INC. | $13.01 | 2019 | |
| Acacia Pharma INC | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rabalais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.